Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis

Objectives. Atorvastatin is a new potent HMG-CoA reductase inhibitor. We ev aluated whether patients with coronary heart disease and severe hypercholes terolaemia showing insufficient LDL (low-density lipoprotein) cholesterol r eduction despite combined therapy with simvastatin and regular LDL apheresi s will benefit from atorvastatin therapy. Setting. Tertiary care centre, university hospital. Methods. In 21 patients treated by LDL apheresis, concomitant simvastatin t herapy (40 mg day(-1)) was replaced by atorvastatin (40 mg day(-1)) and inc reased to 60 and 80 mg day(-1) (each for 3 months) if no side-effects were reported and NCEP treatment goals were not reached. Results. In 20 of 21 patients (95%), atorvastatin resulted in significant r eduction of LDL cholesterol compared with simvastatin (by 10%, additional 8 % and additional 1%, with 40, 60 and 80 mg day(-1) respectively). In four p atients, NCEP treatment goals were reached (in three by atorvastatin alone, and in one by atorvastatin and apheresis). Patients with little reduction in LDL cholesterol to 40 mg day(-1) atorvastatin benefited most by increasi ng the dose to 60 mg day(-1) (additional 13% reduction),whilst those respon ding to atorvastatin 40 mg day(-1) benefited less (additional 1.9% reductio n). During atorvastatin therapy, significantly less plasma had to be treate d during apheresis resulting in shorter apheresis time. Eight patients (38% ) reported side-effects, resulting in discontinuation of atorvastatin in th ree (14%) and dose reduction in five patients (24%), whilst no elevation of biochemical markers was observed. Conclusion. Concomitant atorvastatin therapy is superior to simvastatin the rapy in patients with severe hypercholesterolaemia treated with regular LDL apheresis, but is associated with a high rate of subjective side-effects.